CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications.
paper
Cited
Public
Unavailable
- Authors
- Jagerovic, Nadine; Fernandez-Fernandez, Cristina; Goya, Pilar
- Year
- 2008
- Journal
- Current topics in medicinal chemistry
- PMID
- 18289089
- DOI
- 10.2174/156802608783498050
During the last decade there has been a growing interest towards the modulation of the cannabinoid CB1 receptor. The identification of CB1 cannabinoid receptor antagonists has been one of the major advances in cannabinoid research. Thus, the development of these ligands has opened new therapeutic applications. Since the discovery of the first cannabinoid receptor antagonist, rimonabant, by Sanofi in 1994, a large number of structural variations within this chemical series of 1,5-diarylpyrazoles have been described. So far, all attempts to identify novel structures for CB1 antagonists have been based on one or more pharmacophoric elements of the rimonabant structure. The advanced clinical trials of rimonabant confirm the therapeutic potential value of CB1 antagonists for the treatment of obesity. In addition, the results of pharmacological and clinical studies reveal other effective pharmacotherapeutic applications. The current review will mainly focus on the structure-activity relationships that have been established for antagonists/inverse agonists that bind to the CB1 cannabinoid receptors and on their therapeutic applications.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | 2009 | 19016476 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery. | Shen SY et al. | β | 2025 | β |
| The development and therapeutic potential of classical and next-generation cannabinoid ligands. | MuΓ±oz-Canales V et al. | β | 2025 | β |
| Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. | Lago-Fernandez A et al. | β | 2021 | β |
| Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. | Nguyen T et al. | β | 2019 | β |
| Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. | Aghazadeh Tabrizi M et al. | β | 2018 | β |
| Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases. | Prandi C et al. | β | 2018 | β |
| Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions. | Jenkin KA et al. | β | 2015 | β |
| Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. | Nguyen T et al. | β | 2015 | β |
| Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. | FernΓ‘ndez-FernΓ‘ndez C et al. | β | 2014 | β |
| Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). | German N et al. | β | 2014 | β |
| Bivalent ligands that target ΞΌ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. | Le Naour M et al. | β | 2013 | β |
| Chromenopyrazoles: non-psychoactive and selective CBβ cannabinoid agonists with peripheral antinociceptive properties. | Cumella J et al. | β | 2012 | β |
| Solid phase synthesis of 1,5-diarylpyrazole-4-carboxamides: discovery of antagonists of the CB-1 receptor. | Pendri A et al. | β | 2012 | β |
| Antagonist-elicited cannabis withdrawal in humans. | Gorelick DA et al. | β | 2011 | β |
| Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate. | Ratcliffe P et al. | β | 2011 | β |
| Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity. | Kitajima M et al. | β | 2011 | β |
| Microwave-assisted and continuous flow multistep synthesis of 4-(pyrazol-1-yl)carboxanilides. | Obermayer D et al. | β | 2011 | β |
| A method for parallel solid-phase synthesis of iodinated analogs of the cannabinoid receptor type I (CBβ) inverse agonist rimonabant. | Spivey AC et al. | β | 2010 | β |
| Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. | Receveur JM et al. | β | 2010 | β |
| Diaryl piperidines as CB1 receptor antagonists. | Scott JD et al. | β | 2010 | β |
| Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. | Madsen-Duggan CB et al. | β | 2010 | β |
| Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. | Reggio PH | β | 2010 | β |
| Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists. | Cooper M et al. | β | 2010 | β |
| Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1. | Debenham JS et al. | β | 2010 | β |
| Identification and hit-to-lead optimization of a novel class of CB1 antagonists. | Letourneau JJ et al. | β | 2010 | β |
| One-step continuous flow synthesis of highly substituted pyrrole-3-carboxylic acid derivatives via in situ hydrolysis of tert-butyl esters. | Herath A et al. | β | 2010 | β |
| A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant. | Spivey AC et al. | β | 2009 | β |
| Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. | Janero DR et al. | β | 2009 | β |
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | Agrawal A et al. | β | 2009 | β |
| Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. | Janero DR et al. | β | 2009 | β |
| Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. | Debenham JS et al. | β | 2009 | β |
| Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. | LoVerme J et al. | β | 2009 | β |
| Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. | Alvarado M et al. | β | 2008 | β |
| Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis. | Cichero E et al. | β | 2008 | β |
| Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. | Pei Y et al. | β | 2008 | β |